This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Bruker (BRKR) Up 15.7% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?
by Zacks Equity Research
Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.
Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO
by Zacks Equity Research
Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup
by Zacks Equity Research
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Zacks Industry Outlook Highlights Mettler-Toledo and Bruker
by Zacks Equity Research
Mettler-Toledo and Bruker have been highlighted in this Industry Outlook article.
2 Instruments Stocks to Buy From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.
Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 7.69% and 2.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Trade Desk (TTD) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The Trade Desk's (TTD) fourth-quarter 2023 performance is likely to have benefited from the growing CTV momentum and expanding partner base in the United States.
DoorDash (DASH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
DoorDash's (DASH) fourth-quarter 2023 results are likely to benefit from strong total orders and Marketplace GOV.
Why Bruker (BRKR) Might Surprise This Earnings Season
by Zacks Equity Research
Bruker (BRKR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shopify (SHOP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Shopify's (SHOP) fourth-quarter 2023 performance is expected to have benefited from the growing adoption of merchant-friendly solutions despite the challenging macro environment.
IPG Photonics (IPGP) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
IPG Photonics' (IPGP) fourth-quarter 2023 results are likely to suffer from weakness in cutting and marking applications.
Qualys (QLYS) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Qualys (QLYS) delivered earnings and revenue surprises of 12% and 0.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
by Zacks Equity Research
Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.
Insulet (PODD) Gains From Product Innovation, Global Expansion
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
Bruker (BRKR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) to Advance in Lab Automation With New Buyout
by Zacks Equity Research
This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.